DELIVER Study: DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER Stenting

Last updated: January 21, 2014
Sponsor: Medtronic Vascular
Overall Status: Completed

Phase

N/A

Condition

Atherosclerosis

Chest Pain

Coronary Artery Disease

Treatment

N/A

Clinical Study ID

NCT01297257
IP992
  • Ages > 18
  • All Genders

Study Summary

The primary objective of the DELIVER Study is to assess the deliverability of the Resolute Integrity Stent as primary stent or as a secondary cross-over stent following delivery failure of another stent type in real world patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Minimum legal age (18)

  • Acceptable candidate for treatment with a drug-eluting stent in accordance withapplicable guidelines

  • Patient has consented to participate and authorized in writing the collection andrelease of medical information

Exclusion

Exclusion Criteria:

  • Pregnancy

  • Participating in another study that interferes with study endpoints

  • Untreatable hypersensitivity or allergies to aspirin, heparin, clopidogrel,zotarolimus or similar drugs or contrast media

  • Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated

Study Design

Total Participants: 7845
Study Start date:
February 01, 2011
Estimated Completion Date:
April 30, 2013

Connect with a study center

  • Onze Lieve Vrouwe Gasthuis Ziekenhuis

    Amsterdam,
    Netherlands

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.